Unlike the peptides in this list, 5-Amino-1MQ is a small molecule (not a chain of amino acids) but its often discussed in the peptide therapy world for its outsized impact on metabolism
By competitively binding to p53, FOXO4-DRI displaces endogenous FOXO4, causing p53 nuclear exclusion and translocation to mitochondria where it triggers the intrinsic apoptotic pathway through caspase-3/7 activation
the 23 March 2026 Pfizer/Valneva VLA15 (PF-07307405) Phase 3 VALOR readout (73.2% efficacy)
LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
Administration of this peptide has been associated with the release of serotonin in specific brain regions, notably the nigrostriatal areas, and has beneficial effects on dopaminergic systems